Format
Sort by

Send to

Choose Destination

Search results

Items: 2

1.

Functional systemic CD4 immunity is required for clinical responses to PD-L1/PD-1 blockade therapy.

Zuazo M, Arasanz H, Fernández-Hinojal G, García-Granda MJ, Gato M, Bocanegra A, Martínez M, Hernández B, Teijeira L, Morilla I, Lecumberri MJ, Fernández de Lascoiti A, Vera R, Kochan G, Escors D.

EMBO Mol Med. 2019 Jul;11(7):e10293. doi: 10.15252/emmm.201910293. Epub 2019 Jun 6.

2.

PD-L1 Expression in Systemic Immune Cell Populations as a Potential Predictive Biomarker of Responses to PD-L1/PD-1 Blockade Therapy in Lung Cancer.

Bocanegra A, Fernandez-Hinojal G, Zuazo-Ibarra M, Arasanz H, Garcia-Granda MJ, Hernandez C, Ibañez M, Hernandez-Marin B, Martinez-Aguillo M, Lecumberri MJ, Fernandez de Lascoiti A, Teijeira L, Morilla I, Vera R, Escors D, Kochan G.

Int J Mol Sci. 2019 Apr 2;20(7). pii: E1631. doi: 10.3390/ijms20071631.

Supplemental Content

Loading ...
Support Center